Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
10 nov. 2022 07h00 HE
|
Larimar Therapeutics
First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timelineLarimar expects to provide an...
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
07 nov. 2022 16h05 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
20 oct. 2022 08h00 HE
|
Larimar Therapeutics
Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:...
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
19 oct. 2022 16h05 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
16 sept. 2022 13h00 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
Larimar Therapeutics Announces $70 Million Underwritten Offering
14 sept. 2022 07h04 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
14 sept. 2022 07h01 HE
|
Larimar Therapeutics
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management hosting webcast and conference call today at 8:30 a.m. ET BALA...
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
11 août 2022 16h05 HE
|
Larimar Therapeutics
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose...
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
28 juil. 2022 16h05 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
28 juin 2022 08h00 HE
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...